Prostate cancer is the most commonly diagnosed cancer in men and is the second most common cause of male death from cancer. In 2014, approximately 233,000 men in the U.S. will be diagnosed with prostate cancer and an estimated 29,480 will die from it. In addition, there are major population disparities in prostate cancer incidence and mortality, with African American men experiencing 2.5 times greater risk of prostate cancer death compared to Caucasian men. The Prostate Cancer Research Program prioritizes research that will 1) develop better tools for early detection of clinically relevant disease, 2) distinguish aggressive from indolent disease in men newly diagnosed with prostate cancer, 3) develop effective treatments and address mechanisms of resistance for men with high risk or metastatic prostate cancer, and 4) develop strategies to optimize the physical and mental health of men with prostate cancer. The focus areas for funded research include biomarker development, genetics, imaging, mechanisms of resistance, survivorship and palliative care, therapy, and tumor and microenvironment biology.
PCRP-Supported Key Research Resources
- $1.37 billion FY97-FY14
- $80.0 million FY15